

**Supplementary Table 2: Moderate subgroup: Statistical Analysis of Primary and Secondary outcomes.**

		Moderate		Odds Ratio (95% CI)	Significance	
Parameters		C3 Group	Non C3 Group			
Sample Size (n)		25	25			
Sex	Male	14 (56.0%)	23 (92.0%)			
	Female	11 (44.0%)	2 (8.0%)			
Risk Factor	Age >60	10 (40.0%)	6 (24.0%)	2.11 (0.62, 7.13)	Not Significant	
	Unilateral pneumonia	4 (16.0%)	1 (4.0%)	4.57 (0.47, 44.17)	Not Significant	
	Bilateral pneumonia	20 (80.0%)	24 (96.0%)	0.17 (0.02, 1.55)	Not Significant	
	Fever	20 (80.0%)	17 (68.0%)	1.88 (0.52, 6.84)	Not Significant	
	Cold	11 (44.0%)	8 (32.0%)	1.67 (0.53, 5.29)	Not Significant	
	Cough	18 (72.0%)	16 (64.0%)	1.45 (0.44, 4.78)	Not Significant	
	Sore throat	3 (12.0%)	1 (4.0%)	3.27 (0.32, 33.84)	Not Significant	
	Sneezing	0 (0.0%)	0 (0.0%)		Not Applicable	
	Runny nose	0 (0.0%)	1 (4.0%)		Not Applicable	
	Shortness of breath	6 (24.0%)	15 (60.0%)	0.21 (0.06, 0.71)	Significant	
	Headache	5 (20.0%)	1 (4.0%)	6.00 (0.65, 55.66)	Not Significant	
	Diarrhoea	1 (4.0%)	1 (4.0%)	1.00 (0.06, 16.93)	Not Significant	
	Myalgia	6 (24.0%)	2 (8.0%)	3.63 (0.66, 20.12)	Not Significant	
	Fatigue	7 (28.0%)	2 (8.0%)	4.47 (0.83, 24.19)	Not Significant	
	Loss of taste	1 (4.0%)	0 (0.0%)		Not Applicable	
	Symptoms<6d	22 (88.0%)	21 (84.0%)	1.40 (0.28, 7.00)	Not Significant	
	Symptoms>6d	3 (12.0%)	3 (12.0%)	1.00 (0.18, 5.51)	Not Significant	
PO2	Patient showed red flag signs	Yes	13 (52.0%)	25 (100.0%)		Not Applicable
		No	13 (52.0%)	0 (0.0%)		Not Applicable
PO3	Patient maintained SpO2 above 94% on room air throughout the stay	Yes	14 (56.0%)	2 (8.0%)	14.64 (2.82, 75.96)	Significant
		No	12 (48.0%)	23 (92.0%)	0.08 (0.02, 0.42)	Significant
PO4	Number of days patient could not maintain SpO2 above 94% on room air	No	5 (20.0%)	1 (4.0%)	6.00 (0.65, 55.66)	Not Significant
PO5	Patient required Oxygen therapy	Yes	13 (52.0%)	25 (100.0%)		Not Applicable
		No	12 (48.0%)	0 (0.0%)		Not Applicable
PO7	Patient required Oxygen therapy with high flow nasal cannula (HFNC)	Yes	0 (0.0%)	9 (36.0%)		Not Applicable
		No	25 (100.0%)	16 (64.0%)		Not Applicable
PO8	Patient failed to maintain SpO2 more than 88 % despite of oxygenation	Yes	0 (0.0%)	6 (24.0%)		Not Applicable
		No	25 (100.0%)	19 (76.0%)		Not Applicable
PO9	intubation	Yes	0 (0.0%)	0 (0.0%)		Not Applicable
		No	15 (60.0%)	17 (68.0%)	0.71 (0.22, 2.25)	Not Significant
	mechanical ventilation (noninvasive / invasive)	MV-NI	0 (0.0%)	6 (24.0%)		Not Applicable
		MV-I	0 (0.0%)	0 (0.0%)		Not Applicable
PO10	CRP rise		14 (56.0%)	24 (96.0%)	0.05 (0.01, 0.46)	Significant
	CRP decline		0 (0.0%)	0 (0.0%)		Not Applicable
	CRP approximately same		6 (24.0%)	0 (0.0%)		Not Applicable
	D-Dimer rise		3 (12.0%)	6 (24.0%)	0.43 (0.09, 1.97)	Not Significant
	D-Dimer decline		0 (0.0%)	0 (0.0%)		Not Applicable
	D-Dimer approximately same		7 (28.0%)	1 (4.0%)	9.33 (1.05, 82.78)	Significant
	N/L>3.5		9 (36.0%)	11 (44.0%)	0.72 (0.23, 2.23)	Not Significant
N/L<3.5		6 (24.0%)	6 (24.0%)	1.00 (0.27, 3.66)	Not Significant	
PO11	Chest X Ray abnormalities	Yes	24 (96.0%)	25 (100.0%)		Not Applicable
		No	1 (4.0%)	0 (0.0%)		Not Applicable
PO12	Patient required COVID CARP protocol	Yes	11 (44.0%)	22 (88.0%)	0.11 (0.03, 0.45)	Significant
		No	14 (56.0%)	3 (12.0%)	9.33 (2.21, 39.46)	Significant
PO13	Patient required LMW Heparin	Yes	14 (56.0%)	24 (96.0%)	0.05 (0.01, 0.46)	Significant
		No	11 (44.0%)	1 (4.0%)	18.86 (2.20, 161.99)	Significant
PO14	Patient required Remdesivir	Yes	7 (28.0%)	22 (88.0%)	0.05 (0.01, 0.24)	Significant
		No	18 (72.0%)	3 (12.0%)	18.86 (4.25, 83.59)	Significant
PO15	Patient required cytokine storm treatment eg. Tocilizumab	Yes	0 (0.0%)	5 (20.0%)		Not Applicable
		No	25 (100.0%)	20 (80.0%)		Not Applicable
SO2	Duration of hospitalisation	<10 days	25 (100.0%)	11 (44.0%)		Not Applicable
		10-14 day	0 (0.0%)	10 (40.0%)		Not Applicable
		>14days	0 (0.0%)	4 (16.0%)		Not Applicable
SO3	Thromboembolic events	Yes	0 (0.0%)	4 (16.0%)		Not Applicable
		No	25 (100.0%)	21 (84.0%)		Not Applicable
	Pulmonary fibrosis	Yes	0 (0.0%)	12 (48.0%)		Not Applicable
		No	25 (100.0%)	13 (52.0%)		Not Applicable
SO4	Death related to SARS CoV2 and causes of mortality	Yes	0 (0.0%)	5 (20.0%)		Not Applicable
		No	25 (100.0%)	20 (80.0%)		Not Applicable
ADR1	Nausea, Vomiting, Abdominal discomfort	Yes	5 (20.0%)	0 (0.0%)		Not Applicable
		No	20 (80.0%)	25 (100.0%)		Not Applicable
ADR2	Skin Rash	Yes	0 (0.0%)	0 (0.0%)		Not Applicable
		No	25 (100.0%)	25 (100.0%)		Not Applicable
ADR3	Burning micturition	Yes	2 (8.0%)	0 (0.0%)		Not Applicable
		No	23 (92.0%)	25 (100.0%)		Not Applicable
ADR4	Excessive bleeding	Yes	0 (0.0%)	0 (0.0%)		Not Applicable
		No	25 (100.0%)	25 (100.0%)		Not Applicable

PO - Primary Outcome; SO - Secondary Outcome; ADR - Adverse drug reaction

If 95% confidence interval for odds ratio contains value 1, then the parameter is not significant at 5% level.